Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
But supplements may rely on preliminary or incomplete data, so its less clear what effect they will have on you
Post-Reconstitution Storage: Store reconstituted solutions at 28C (refrigerated) and use within 1428 days to ensure stability
Eating smaller, frequent meals instead of three large meals also helps prevent overwhelming your digestive system
Retatrutide is an investigational triple hormone receptor agonist currently in clinical development for the treatment of obesity and type 2 diabetes
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
US$ 23.03
US$ 29.91
US$ 24.99
US$ 22.95
US$ 21.95
